Table 5.
Responsiveness of the Borg dyspnea score
| Study | Reference | Baseline BDS | Change in BDS |
|---|---|---|---|
| Ambrisentan (ARIES 1&2) | 12 | 4.0 ± 0.3 | −0.9 ± 0.3* at 12 wk |
| −1.3 ± 0.3* at 24 wk | |||
| Sildenafil (SUPER) | 7 | Not reported | At 12 wk: |
| −1 (95% CI, −1 to 0) in 20 mg | |||
| 0 (95% CI, −1 to 0) in 40 mg | |||
| −1 (95% CI, −1.5 to 0) in 80 mg | |||
| Bosentan (BREATHE-1) | 9 | At 16 wk: | |
| 3.3 ± 0.3 in 125 mg | −0.1 ± 0.2 in 125 mg | ||
| 3.8 ± 0.2 in 250 mg | −0.6 ± 0.2 in 250 mg | ||
| 3.8 ± 0.2 in placebo | +0.3 ± 0.2 in placebo | ||
| Combination ambrisentan + tadalafil for PAH (AMBITION) | 16 | Not reported | At 24 wk: median (IQR) |
| Ambrisentan + tadalafil | −1.00 (−2.00 to 0.50) | ||
| Ambrisentan | −0.50 (−1.50 to 0.50) | ||
| Tadalafil | −0.50 (−2.00 to 0.88) | ||
| Riociguat (PATENT-1) | 15 | At 12 wk: | |
| 4 ± 2 in 2.5 mg | −0.4 ± 1.7* in 2.5 mg | ||
| 3.9 ± 2.5 in placebo | +0.1 ± 2.1 in placebo |
Definition of abbreviations: AMBITION = Ambrisentan and Tadalafil in Patients with Pulmonary Arterial Hypertension; ARIES = Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies; BDS = Borg dyspnea score; BREATHE-1 = Bosentan Randomized Trial of Endothelin Antagonist Trial-1; CI = confidence interval; IQR = interquartile range; PAH = pulmonary arterial hypertension; PATENT-1 = Hypertension Soluble Guanylate Cyclase–Stimulator Trial 1; SUPER = Sildenafil Use in Pulmonary Arterial Hypertension.
*
Indicates P value < 0.01.